Ka'e Aude Christelle, Santoro Maria Mercedes, Duca Leonardo, Chenwi Collins Ambe, Ngoufack Jagni Semengue Ezechiel, Nka Alex Durand, Etame Naomi-Karell, Togna Pabo Willy Leroi, Beloumou Grace, Mpouel Marie Laure, Djupsa Sandrine, Takou Desire, Sosso Samuel Martin, Tchidjou Hyppolite K, Colizzi Vittorio, Halle-Ekane Gregory-Edie, Perno Carlo-Federico, Lewin Sharon, Jones R Brad, Tiemessen Caroline T, Ceccherini-Silberstein Francesca, Fokam Joseph
Chantal Biya International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaounde, Cameroon.
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
J Virus Erad. 2024 Mar 30;10(1):100367. doi: 10.1016/j.jve.2024.100367. eCollection 2024 Mar.
With the advent of antiretroviral therapy (ART), most children living with HIV in sub-Saharan Africa (SSA) are growing toward adolescence, with scarcity of evidence on the size of viral reservoirs to enhance paediatric cure research strategies. This study aims to compare HIV-1 proviral DNA levels according to virological response among adolescents living with perinatally acquired HIV-1 (ALPHIV) and identify associated-factors in the Cameroonian context.
In this observational cohort study, HIV-1 RNA viremia and CD4 T-cell count were assessed through RT-PCR and flow cytometry respectively at three time-points over 18 months of observation. At the third time-point, 80 randomly-selected participants were classified as with viremia (≥50 HIV-1 copies/mL; n = 40) or without viremia (<50 HIV-1 copies/mL; n = 40); immune-competent (≥500 CD4 T cells/mm) or immunocompromised (<500 CD4 T cells/mm). Among these participants, total HIV-1 DNA load was quantified through droplet digital PCR using Bio-Rad QX200.
Of the 80 randomly-selected adolescents, median [IQR] age was 15 (13-17) years, 56.2% were female, duration on ART was 9.3 [5.4-12.2] years. Among the 40 viremic ones (median viremia 7312 [283-71482]) HIV-1 copies/ml, 75.0% (30/40) were in virological failure (≥1000 HIV-1 copies/ml), while median of CD4 T cells were 494 [360-793] cell/mm with 48.8% (39/80) immunocompromised. No significant variation in HIV-1 RNA viremia and CD4 T cell count was observed between the three time-points, and 13.7% (11/80) adolescents remained aviremic and immune-competent throughout (stable adolescents). A positive and moderate correlation (r = 0.59; p < 0.001) was found between HIV-1 DNA levels and HIV- 1 RNA viremia. Regarding the CD4 T cell count, a negative and weak correlation (r = -0.28; p = 0.014) was found with HIV-1 DNA loads only among adolescents with viremia. Starting ART within the first year of life, ART for over 9 years and aviremia appear as predictors of low HIV-1 DNA loads.
Among ALPHIV, high HIV-1 RNA indicates an elevated viral reservoir size, representing a drawback to cure research. Interestingly, early ART initiation and longer ARTduration lead to sustained viral control and limited HIV-1 reservoir size. As limited size of viral reservoir appears consistent with viral control and immune competence, adolescents with sustained viral control (about 14% of this target population) would be candidates for analytical ART interruptions toward establishing paediatric post-treatment controllers in SSA.
随着抗逆转录病毒疗法(ART)的出现,撒哈拉以南非洲(SSA)的大多数感染艾滋病毒的儿童正步入青春期,但关于病毒储存库大小的证据匮乏,这不利于加强儿科治愈研究策略。本研究旨在比较围产期感染艾滋病毒-1(ALPHIV)的青少年中根据病毒学反应的艾滋病毒-1前病毒DNA水平,并在喀麦隆背景下确定相关因素。
在这项观察性队列研究中,在18个月的观察期内的三个时间点分别通过逆转录聚合酶链反应(RT-PCR)和流式细胞术评估艾滋病毒-1 RNA病毒血症和CD4 T细胞计数。在第三个时间点,80名随机选择的参与者被分类为有病毒血症(≥50个艾滋病毒-1拷贝/毫升;n = 40)或无病毒血症(<50个艾滋病毒-1拷贝/毫升;n = 40);免疫功能正常(≥500个CD4 T细胞/立方毫米)或免疫功能低下(<500个CD4 T细胞/立方毫米)。在这些参与者中,使用伯乐QX200通过液滴数字PCR对艾滋病毒-1总DNA载量进行定量。
在80名随机选择的青少年中,中位[四分位间距]年龄为15(13 - 17)岁,56.2%为女性,接受抗逆转录病毒治疗的时间为9.3[5.4 - 12.2]年。在40名有病毒血症者(中位病毒血症为7312[283 - 71482]个艾滋病毒-1拷贝/毫升)中,75.0%(30/40)处于病毒学失败(≥1000个艾滋病毒-1拷贝/毫升),而CD4 T细胞的中位数为494[360 - 793]个细胞/立方毫米,48.8%(39/80)免疫功能低下。在三个时间点之间未观察到艾滋病毒-1 RNA病毒血症和CD4 T细胞计数有显著变化,13.7%(11/80)的青少年始终无病毒血症且免疫功能正常(稳定青少年)。在艾滋病毒-1 DNA水平与艾滋病毒-1 RNA病毒血症之间发现正相关且中等程度相关(r = 0.59;p < 0.001)。关于CD4 T细胞计数,仅在有病毒血症的青少年中发现与艾滋病毒-1 DNA载量呈负相关且弱相关(r = -0.28;p = 0.014)。在生命的第一年内开始抗逆转录病毒治疗、接受抗逆转录病毒治疗超过9年和无病毒血症似乎是低艾滋病毒-1 DNA载量的预测因素。
在ALPHIV中,高艾滋病毒-1 RNA表明病毒储存库大小增加,这是治愈研究的一个障碍。有趣的是,早期开始抗逆转录病毒治疗和更长的抗逆转录病毒治疗持续时间导致持续的病毒控制和有限的艾滋病毒-1储存库大小。由于有限的病毒储存库大小似乎与病毒控制和免疫能力一致,持续病毒控制的青少年(约占该目标人群的14%)将成为在SSA进行分析性抗逆转录病毒治疗中断以建立儿科治疗后控制器的候选者。